ASH Clinical News Focus on Myeloid Malignancies | Page 27

RESONATE TM -2 FRONTLINE DATA
RESONATE TM -2 was a multicenter, randomized 1:1, open-label, Phase 3 trial
of IMBRUVICA® vs chlorambucil in frontline CLL/SLL patients ≥65 years (N=269) 2,3
Patients with 17p deletion were not included in the RESONATE TM -2 trial 3
EXTENDED
OVERALL SURVIVAL
PROLONGED
PROGRESSION-FREE
SURVIVAL
IMBRUVICA® signifi cantly extended
OS vs chlorambucil 2
IMBRUVICA® signifi cantly extended PFS
vs chlorambucil 2,3
Statistically signifi cant
reduction in risk of death 2
2,3
56%
HR=0.44
(95% CI: 0.21, 0.92)
41% of patients
2,3
crossed over to IMBRUVICA®
Estimated survival rates at 24 months
95% IMBRUVICA®
(95% CI: 89, 97)
84% chlorambucil
PRIMARY ENDPOINT: PFS
(95% CI: 77, 90)
• Median follow-up was 18 months